ARCT - Arcturus Therapeutics announces collaboration with CSL Seqirus

• Arcturus Therapeutics ( NASDAQ: ARCT ) surges 32,4% after-hours on Tuesday after the firm enters a strategic collaboration with CSL Seqirus to provide former with a license to their self-amplifying mRNA technology to support the research, development, manufacture, and commercialization of vaccines for SARS-CoV-2, influenza, pandemic preparedness, as well as three other globally prevalent respiratory infectious diseases
• CSL Seqirus' vaccine portfolio includes the world's second largest influenza vaccine franchise.
• CSL Seqirus is part of CSL Limited ( OTCPK:CSLLY ).
• Arcturus to receive upfront payment of $200M and more than $4B in potential development and commercial milestones.
• 40% profit sharing for COVID-19 vaccines, up to double digit royalties for influenza, pandemic preparedness and three additional respiratory infectious disease vaccines.
• The integration combines Arcturus’ self-amplifying mRNA vaccine technologies with CSL’s world-leading capabilities as a commercial scale manufacturer and global distributor of influenza and pandemic vaccines.

For further details see: